Clinical Trial Update: PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating neoadjuvant dostarlimab with short-course radiotherapy in a watch-and-wait strategy for mismatch repair-deficient or MSI-H locally adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) | Phase 3 | Status: RECRUITING